Compare Oxford Lane Capital Corp (OXLC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Oxford Lane Capital Corp trades at $8.22 (market cap $806.30M), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.2× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 29.18% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 51 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| OXLC | TVTX | |
|---|---|---|
Market Cap | $806.30M | $5.02B |
Volume | 1,199,574 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $16.02 | $67.52 |
52-Week Low | $8.15 | $26.79 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $1.20B | $5.15B |
Dividend Yield | 29.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
